The epidemiology of breast implant-associated anaplastic large cell lymphoma in Australia and New Zealand confirms the highest risk for grade 4 surface breast implants

Mark Magnusson, Kenneth Beath, Rodney Cooter, Michelle Locke, H. Miles Prince, Elisabeth Elder, Anand K. Deva

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background: The epidemiology and implant-specific risk for breast implant-associated (BIA) anaplastic large cell lymphoma (ALCL) has been previously reported for Australia and New Zealand. The authors now present updated data and risk assessment since their last report. Methods: New cases in Australia and New Zealand were identified and analyzed. Updated sales data from three leading breast implant manufacturers (i.e., Mentor, Allergan, and Silimed) were secured to estimate implant-specific risk. Results: A total of 26 new cases of BIA-ALCL were diagnosed between January of 2017 and April of 2018, increasing the total number of confirmed cases in Australia and New Zealand to 81. This represents a 47 percent increase in the number of reported cases over this period. The mean age and time to development remain unchanged. The implant-specific risk has increased for Silimed polyurethane (23.4 times higher) compared with Biocell, which has remained relatively static (16.5 times higher) compared with Siltex implants. Conclusions: The number of confirmed cases of BIA-ALCL in Australia and New Zealand continues to rise. The implant-specific risk has now changed to reflect a strong link to implant surface area/roughness as a major association with this cancer.

LanguageEnglish
Pages1285-1292
Number of pages8
JournalPlastic and reconstructive surgery
Volume143
Issue number5
DOIs
Publication statusPublished - 1 May 2019

Fingerprint

Anaplastic Large-Cell Lymphoma
Breast Implants
New Zealand
Epidemiology
Mentors
Polyurethanes
Neoplasms

Cite this

@article{a425295b023c48e191b0637ac93c6451,
title = "The epidemiology of breast implant-associated anaplastic large cell lymphoma in Australia and New Zealand confirms the highest risk for grade 4 surface breast implants",
abstract = "Background: The epidemiology and implant-specific risk for breast implant-associated (BIA) anaplastic large cell lymphoma (ALCL) has been previously reported for Australia and New Zealand. The authors now present updated data and risk assessment since their last report. Methods: New cases in Australia and New Zealand were identified and analyzed. Updated sales data from three leading breast implant manufacturers (i.e., Mentor, Allergan, and Silimed) were secured to estimate implant-specific risk. Results: A total of 26 new cases of BIA-ALCL were diagnosed between January of 2017 and April of 2018, increasing the total number of confirmed cases in Australia and New Zealand to 81. This represents a 47 percent increase in the number of reported cases over this period. The mean age and time to development remain unchanged. The implant-specific risk has increased for Silimed polyurethane (23.4 times higher) compared with Biocell, which has remained relatively static (16.5 times higher) compared with Siltex implants. Conclusions: The number of confirmed cases of BIA-ALCL in Australia and New Zealand continues to rise. The implant-specific risk has now changed to reflect a strong link to implant surface area/roughness as a major association with this cancer.",
author = "Mark Magnusson and Kenneth Beath and Rodney Cooter and Michelle Locke and Prince, {H. Miles} and Elisabeth Elder and Deva, {Anand K.}",
year = "2019",
month = "5",
day = "1",
doi = "10.1097/PRS.0000000000005500",
language = "English",
volume = "143",
pages = "1285--1292",
journal = "Plastic and reconstructive surgery",
issn = "0032-1052",
publisher = "Lippincott Williams & Wilkins",
number = "5",

}

The epidemiology of breast implant-associated anaplastic large cell lymphoma in Australia and New Zealand confirms the highest risk for grade 4 surface breast implants. / Magnusson, Mark; Beath, Kenneth; Cooter, Rodney; Locke, Michelle; Prince, H. Miles; Elder, Elisabeth; Deva, Anand K.

In: Plastic and reconstructive surgery, Vol. 143, No. 5, 01.05.2019, p. 1285-1292.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - The epidemiology of breast implant-associated anaplastic large cell lymphoma in Australia and New Zealand confirms the highest risk for grade 4 surface breast implants

AU - Magnusson,Mark

AU - Beath,Kenneth

AU - Cooter,Rodney

AU - Locke,Michelle

AU - Prince,H. Miles

AU - Elder,Elisabeth

AU - Deva,Anand K.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Background: The epidemiology and implant-specific risk for breast implant-associated (BIA) anaplastic large cell lymphoma (ALCL) has been previously reported for Australia and New Zealand. The authors now present updated data and risk assessment since their last report. Methods: New cases in Australia and New Zealand were identified and analyzed. Updated sales data from three leading breast implant manufacturers (i.e., Mentor, Allergan, and Silimed) were secured to estimate implant-specific risk. Results: A total of 26 new cases of BIA-ALCL were diagnosed between January of 2017 and April of 2018, increasing the total number of confirmed cases in Australia and New Zealand to 81. This represents a 47 percent increase in the number of reported cases over this period. The mean age and time to development remain unchanged. The implant-specific risk has increased for Silimed polyurethane (23.4 times higher) compared with Biocell, which has remained relatively static (16.5 times higher) compared with Siltex implants. Conclusions: The number of confirmed cases of BIA-ALCL in Australia and New Zealand continues to rise. The implant-specific risk has now changed to reflect a strong link to implant surface area/roughness as a major association with this cancer.

AB - Background: The epidemiology and implant-specific risk for breast implant-associated (BIA) anaplastic large cell lymphoma (ALCL) has been previously reported for Australia and New Zealand. The authors now present updated data and risk assessment since their last report. Methods: New cases in Australia and New Zealand were identified and analyzed. Updated sales data from three leading breast implant manufacturers (i.e., Mentor, Allergan, and Silimed) were secured to estimate implant-specific risk. Results: A total of 26 new cases of BIA-ALCL were diagnosed between January of 2017 and April of 2018, increasing the total number of confirmed cases in Australia and New Zealand to 81. This represents a 47 percent increase in the number of reported cases over this period. The mean age and time to development remain unchanged. The implant-specific risk has increased for Silimed polyurethane (23.4 times higher) compared with Biocell, which has remained relatively static (16.5 times higher) compared with Siltex implants. Conclusions: The number of confirmed cases of BIA-ALCL in Australia and New Zealand continues to rise. The implant-specific risk has now changed to reflect a strong link to implant surface area/roughness as a major association with this cancer.

UR - http://www.scopus.com/inward/record.url?scp=85065437375&partnerID=8YFLogxK

U2 - 10.1097/PRS.0000000000005500

DO - 10.1097/PRS.0000000000005500

M3 - Article

VL - 143

SP - 1285

EP - 1292

JO - Plastic and reconstructive surgery

T2 - Plastic and reconstructive surgery

JF - Plastic and reconstructive surgery

SN - 0032-1052

IS - 5

ER -